Autoimmune Diseases and Cannabis Part 4 – Irritable Bowel Syndrome
In the fourth installment of this 10-part series, we take an in-depth look at utilizing cannabinoid therapies for one of the most common autoimmune diseases, Irritable Bowel Syndrome, most commonly known as IBS. This autoimmune disorder does not have one underlying cause, but there are a wide variety of different things that are believed to be underlying factors in the development of IBS in patients. This autoimmune disorder affects approximately 10 to 15% of the United States population equaling somewhere between 25 to 45 million people that live with IBS daily in the United States alone. This autoimmune disease is more common in women than in men and is characterized by a wide variety of different debilitating symptoms which occur within the abdomen and gut. Scientific research to date offers significant hope for the utilization of cannabinoids, such as CBD and THC, for the treatment of IBS and its various symptoms. A systematic review of randomized and non-randomized studies regarding cannabinoids for IBS performed in 2020 found that cannabinoids could offer significant relief from many of the common IBS symptoms experienced by patients. Check out this article to learn more about how cannabinoid therapies may help those living with Irritable Bowel Syndrome.